| Literature DB >> 3258211 |
J M Andrieu1, P Even, A Venet, J M Tourani, M Stern, W Lowenstein, C Audroin, D Eme, D Masson, H Sors.
Abstract
Cyclosporin (7.5 mg/kg daily) was given to 8 AIDS patients for 17-66 days and to 25 HIV-seropositive non-AIDS patients, 15 with stage II (T4 cells/microliter greater than or equal to 300, less than 600) and 10 with stage III (T4/microliter less than 300), for 3-6 months with the hypothesis that the drug could inhibit both HIV replication and the potential autoimmune component of HIV disease. A sustained increase over 600 T4/microliter occurred in 7 patients with stage II and 1 with stage III. T8 cells significantly decreased in most patients and lymphadenopathy disappeared in 14/16. After cyclosporin withdrawal T4 and T8 cells as well as lymphadenopathy returned to pretreatment status. Cyclosporin side effects (hypertension, creatinine increase, and anemia) were moderate and reversible. These results might stimulate biological research as well as clinical trials with cyclosporin in selected groups of HIV-seropositive subjects with the aim of delaying or preventing AIDS occurrence.Entities:
Mesh：
Substances：
Year: 1988 PMID： 3258211 DOI： 10.1016/0090-1229(88)90071-2
Source DB: PubMed Journal: Clin Immunol Immunopathol ISSN： 0090-1229